Immunome (NASDAQ:IMNM) CEO Clay Siegall Buys 7,278 Shares of Stock

Immunome, Inc. (NASDAQ:IMNM) CEO Clay Siegall acquired 7,278 shares of the company’s stock in a transaction dated Friday, December 19th. The shares were bought at an average cost of $20.48 per share, with a total value of $149,053.44. Following the purchase, the chief executive officer owned 860,525 shares of the company’s stock, valued at approximately $17,623,552. This trade represents a 0.85% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Immunome Stock Performance

Shares of Immunome stock opened at $22.03 on Tuesday. Immunome, Inc. has a 52-week low of $5.15 and a 52-week high of $25.30. The company’s 50 day moving average price is $17.84 and its 200-day moving average price is $12.82. The stock has a market capitalization of $2.02 billion, a price-to-earnings ratio of -7.47 and a beta of 2.17.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.08). Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.50%. As a group, equities research analysts forecast that Immunome, Inc. will post -2.21 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on IMNM. Craig Hallum assumed coverage on shares of Immunome in a report on Friday, September 5th. They set a “buy” rating and a $26.00 target price for the company. Wall Street Zen raised Immunome from a “sell” rating to a “hold” rating in a research report on Saturday, November 22nd. Guggenheim increased their price objective on Immunome from $25.00 to $35.00 and gave the stock a “buy” rating in a report on Tuesday, December 16th. The Goldman Sachs Group started coverage on Immunome in a research report on Monday, September 22nd. They issued a “buy” rating and a $26.00 price objective on the stock. Finally, Stephens upped their target price on Immunome from $25.00 to $33.00 and gave the company an “overweight” rating in a report on Monday, November 17th. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Immunome currently has an average rating of “Moderate Buy” and an average price target of $30.09.

Institutional Trading of Immunome

Large investors have recently bought and sold shares of the company. Assetmark Inc. purchased a new position in shares of Immunome during the 3rd quarter worth approximately $39,000. BNP Paribas Financial Markets boosted its position in shares of Immunome by 81.8% during the second quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock valued at $60,000 after purchasing an additional 2,909 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in Immunome by 121.2% in the second quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company’s stock worth $65,000 after purchasing an additional 3,802 shares during the period. BIT Capital GmbH bought a new position in Immunome in the third quarter worth $69,000. Finally, Russell Investments Group Ltd. bought a new position in Immunome in the third quarter worth $76,000. 44.58% of the stock is owned by institutional investors.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.